Supergut, the first clinically validated nutrition brand for gut health, is now available at Target stores across the U.S. and online at Target.com. The brand’s exclusive Target lineup features its…
MEDiC Life Sciences, a biotech startup based in Silicon Valley, has announced a new research collaboration with Hanmi Pharmaceutical, a prominent biopharmaceutical company in Korea. The partnership aims to identify…
Biogen Inc. (Nasdaq: BIIB) – Biogen announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to felzartamab, an investigational anti-CD38 monoclonal antibody. This…
GSK plc (LSE/NYSE: GSK) has announced new findings from the AReSVi-006 Phase III trial, which assessed the effectiveness of a single dose of Arexvy, a recombinant adjuvanted vaccine for respiratory…
Veterinary technicians play a vital role in the veterinary field, carrying out important tasks such as assisting in surgeries, conducting diagnostic tests, and providing emergency care. To meet the increasing…
Gilead Sciences, Inc. (Nasdaq: GILD) has released new data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), highlighting the efficacy and safety of lenacapavir, an injectable HIV-1 capsid inhibitor,…
Gilead Sciences, Inc. has announced the presentation of new findings from its antiviral research and development programs at IDWeek 2024, scheduled for October 16-19. The presentations will include data from…
Pfizer Inc. (NYSE: PFE) has announced encouraging topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study, evaluating TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)…
Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing bleeding episodes in adults…
AstraZeneca’s Airsupra (albuterol/budesonide) has demonstrated promising outcomes in the BATURA Phase IIIb trial, achieving its primary endpoint by significantly and meaningfully reducing the risk of severe asthma exacerbations when used…
Roche (SIX: RO, ROG; OTCQX: RHHBY) presented promising two-year findings from the ongoing RAINBOWFISH study at the 29th World Muscle Society (WMS) Congress, held from October 8-12, 2024. The study…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Itovebi™ (inavolisib) for use in combination with palbociclib (Ibrance®) and fulvestrant to treat…